Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acitretin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 12/20 | 0.45 |
| ▸ | RARG known ✓ | P13631 | 9/20 | 0.45 |
| ▸ | RARA known ✓ | P10276 | 6/20 | 0.45 |
| ▸ | RARB known ✓ | P10826 | 6/20 | 0.45 |
| ▸ | RXRB known ✓ | P28702 | 4/20 | 0.45 |
| ▸ | RXRG known ✓ | P48443 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acitretin SCHEMBL159360 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL29883491 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5028866 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL3759 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL2280089 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5053805 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL10750446 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL4443721 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL9856594 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| SCHEMBL10750080 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119394085-A | Real-time monitoring method and system for characteristics of cooling tower of wet cooling unit | 上海明华电力科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20240420847-A1 | SYSTEM AND METHODS FOR PERFORMING SALIVA-BASED DIAGNOSTIC SCREENINGS | CellectGen, Inc. (US) | 2024-12-19 | — | — | US | claimed |
| WO-2024174011-A1 | LIPOSOME, METHOD FOR PREPARING A LIPOSOME, INTRANASAL COMPOSITION COMPRISING A LIPOSOME, METHOD FOR PREPARING AN INTRANASAL COMPOSITION, KIT AND USE OF THE COMPOSITION | ROSSI BERGMANN BARTIRA (BR) | 2024-08-29 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023133084-A1 | SYSTEM AND METHODS FOR PERFORMING SALIVA-BASED DIAGNOSTIC SCREENINGS | CellectGen, Inc. (US) | 2023-07-13 | — | — | WO | claimed |
| US-12521358-B2 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | RAQUALIA PHARMA INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250172609-A1 | PROBE TESTING APPARATUS, PROBE TESTING SYSTEM AND PROBE CARD | RENESAS ELECTRONICS CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| CN-120044280-A | Probe testing device, probe testing system and probe card | 瑞萨电子株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-119603433-A | Projector automatic focusing method based on gradient calculation and convolution neural network | 佛山得一智能科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240420847-A1 | SYSTEM AND METHODS FOR PERFORMING SALIVA-BASED DIAGNOSTIC SCREENINGS | CellectGen, Inc. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240317815-A1 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA INC (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024174011-A1 | LIPOSOME, METHOD FOR PREPARING A LIPOSOME, INTRANASAL COMPOSITION COMPRISING A LIPOSOME, METHOD FOR PREPARING AN INTRANASAL COMPOSITION, KIT AND USE OF THE COMPOSITION | ROSSI BERGMANN BARTIRA (BR) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023133084-A1 | SYSTEM AND METHODS FOR PERFORMING SALIVA-BASED DIAGNOSTIC SCREENINGS | CellectGen, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-4173639-A1 | METHOD FOR SELECTING CANCER PATIENT FOR WHICH COMBINATION THERAPY OF RETINOID AND CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINED DRUG OF RETINOID AND CANCER TREATMENT AGENT | RaQualia Pharma Inc. (JP) | 2023-05-03 | — | — | EP | disclosed |
| CN-115634198-A | Solvent composition for water-insoluble substances and preparation method and application thereof | 浙江贝灵生物医药有限公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |